SPECIAL EDITION: BoB@JPMThe Business of Biotech podcast took to the streets of San Francisco during the 41st Annual J.P. Morgan Healthcare Conference. This week's episode features a conversation with Sangamo Therapeutics CEO Sandy Macrea, Ph.D., who rationalizes the company's aggressive pipeline development and its decision to invest in multinational AAV and cell therapy manufacturing facilities in France and California. Dr. Macrea zeroes in on the relationship between people and processes that's enabled the company to grow to more than 500 associates working on nearly 20 cell therapy, gene therapy, and genome engineering programs. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!